Brain Scientific（BRSF）株式概要ブレイン・サイエンティフィック社は医療技術企業で、米国内外で神経学とモーション・プロダクトを提供している。 詳細BRSF ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析意味のある時価総額がありません ( $745 )最新の財務報告は1年以上前のものである 株式の流動性は非常に低い すべてのリスクチェックを見るBRSF Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.000699.8% 割安 内在価値ディスカウントEst. Revenue$PastFuture-12m489k2016201920222025202620282031Revenue US$214.6kEarnings US$28.6kAdvancedSet Fair ValueView all narrativesBrain Scientific Inc. 競合他社LogicMarkSymbol: OTCPK:LGMKMarket cap: US$530.9kSTRATA Skin SciencesSymbol: OTCPK:SSKNMarket cap: US$741.9kENvue MedicalSymbol: NasdaqCM:FEEDMarket cap: US$1.0mBluejay DiagnosticsSymbol: NasdaqCM:BJDXMarket cap: US$1.8m価格と性能株価の高値、安値、推移の概要Brain Scientific過去の株価現在の株価US$0.000652週高値US$0.000652週安値US$0.0001ベータ01ヶ月の変化500.00%3ヶ月変化500.00%1年変化n/a3年間の変化-99.90%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースお知らせ • Jan 04Brain Scientific Inc. Announces the Resignation of Fred Anthony as Chief Technology OfficerOn December 29, 2022, Mr. Fred Anthony submitted to the board of directors of Brain Scientific Inc. (the “Company”) his resignation from his position as Chief Technology Officer of the Company, effective December 30, 2022.お知らせ • Dec 03Brain Scientific Appoints Kevin Winterfield as Vice President of Marketing and CommunicationBrain Scientific announced the appointment of Kevin Winterfield as Vice President of Marketing and Communications to accelerate Brain Scientific's strategic growth plan heading into the new year. Kevin Winterfield joins the Brain Scientific team as vice president of marketing and communications. He brings a wealth of marketing and communications experience in the B2B technology space. Winterfield has designed and led successful campaigns with IBM, Consumer Reports, TeamKCI and Bantam Tools to develop brands across identity creation, messaging, launch and sales. He also worked as an EEG and evoked potential technician early in his career and knows firsthand that the wearables market is ripe for rapid innovation. Winterfield will work hand-in-hand with Daniel Cloutier, who recently joined the Brain Scientific team as chief revenue officer.お知らせ • Nov 16Brain Scientific Inc. Announces Release of Improved and Updated NeuroCap™ DeviceBrain Scientific Inc. announced the immediate release of the improved and updated NeuroCap™ device. NeuroCap satisfies the three criteria D&D Medical uses to select new technologies to represent: it provides a safer alternative for the patients and clinicians, it’s innovative and new, and it saves hospitals and patients money. Brain Scientific’s newly improved NeuroCap recently entered production for the company and its distributors to build stock and fulfill customer requests. The improvements to the NeuroCap include a proprietary gel with better conductivity, improved performance adhesive pads, a more conductive, precise ink formulation, and a base of modern blue PET material. Brain Scientific developed the NeuroCap to streamline EEG prep, testing and diagnosis. NeuroCap has 22 pre-gelled electrodes making it a suitable option for most clinical EEG tests, including routine EEGs that are often used for stroke and epilepsy patients. The fixed electrode placement is in accordance with the international 10-20 system. The Brain Scientific NeuroCap is an FDA 510k cleared, pre-gelled disposable EEG headset for clinical use. It allows any clinician to prepare a patient for an EEG exam in a fraction of the time normally spent applying individual electrodes. The NeuroCap can be used in nearly any environment, including rural hospitals, ambulances, private practices and athletic events, vastly expanding access to EEG testing. It is currently available in four sizes, including pediatric sizes.お知らせ • Nov 02Brain Scientific Appoints Daniel Cloutier as Chief Revenue OfficerBrain Scientific announced that Daniel Cloutier is joining the company as its chief revenue officer (CRO) in a move that will help propel the company forward on its mission to revolutionize the medical industry. Cloutier brings extensive experience and knowledge in sales strategy and global distribution. He founded LOK Corporation in 2011 after representing CAS Medical System (CASMED) for eight years as international sales director and launching the FORE-SIGHT cerebral oximetry internationally. Cloutier will lead Brain Scientific’s sales and marketing strategy, leveraging his experience in direct and indirect sales channels and deep relationships across distributors, research institutions and regulators in the medical technology space. Cloutier is also an advisory council member of the Indian Business Organization for Global Investments, a member of the board of directors for the Independent Medical Specialty Dealers Association and Brain Scientific, and a former board member of NeuroFrance Implants and Luminor Medical Technologies. He received his education from HEC Montréal.お知らせ • Aug 25Brain Scientific Announces CE Mark Approval for NeuroCap™ DeviceBrain Scientific Inc. announces receiving the Conformité Européenne (CE) Mark for the NeuroCap™. The CE mark confirms that Brain Scientific meets all European Medical Device Directive requirements to begin commercializing its innovative neurological devices across the European Continent and other CE mark geographies. Brain Scientific has developed two distinct devices to streamline EEG prep, testing, and diagnosis. NeuroCap™ has 22 pre-gelled electrodes making it a suitable option for most clinical EEG tests, including routine EEGs that are often used for stroke and epilepsy patients. The fixed electrode placement is in accordance with the international 10-20 system. NeuroEEG™ is a 21-channel amplifier that provides clinicians with the same quality as traditional EEG equipment. The NeuroCap™ is an FDA 510k cleared, pre-gelled disposable EEG headset for clinical use. The NeuroCap™ allows any clinician to prepare a patient for an EEG exam in a fraction of the time normally spent applying individual electrodes. The NeuroCap™ can be used in nearly any environment, including rural hospitals, ambulances, private practices, and athletic events, vastly expanding access to EEG testing. It is currently available in four sizes, including pediatric sizes.お知らせ • Aug 13Brain Scientific Inc. has filed an IPO in the amount of $12.075 million.Brain Scientific Inc. has filed an IPO in the amount of $12.075 million. Security Name: Units Security Type: Equity/Derivative Unit Transaction Features: New Market Listing最新情報をもっと見るRecent updatesお知らせ • Jan 04Brain Scientific Inc. Announces the Resignation of Fred Anthony as Chief Technology OfficerOn December 29, 2022, Mr. Fred Anthony submitted to the board of directors of Brain Scientific Inc. (the “Company”) his resignation from his position as Chief Technology Officer of the Company, effective December 30, 2022.お知らせ • Dec 03Brain Scientific Appoints Kevin Winterfield as Vice President of Marketing and CommunicationBrain Scientific announced the appointment of Kevin Winterfield as Vice President of Marketing and Communications to accelerate Brain Scientific's strategic growth plan heading into the new year. Kevin Winterfield joins the Brain Scientific team as vice president of marketing and communications. He brings a wealth of marketing and communications experience in the B2B technology space. Winterfield has designed and led successful campaigns with IBM, Consumer Reports, TeamKCI and Bantam Tools to develop brands across identity creation, messaging, launch and sales. He also worked as an EEG and evoked potential technician early in his career and knows firsthand that the wearables market is ripe for rapid innovation. Winterfield will work hand-in-hand with Daniel Cloutier, who recently joined the Brain Scientific team as chief revenue officer.お知らせ • Nov 16Brain Scientific Inc. Announces Release of Improved and Updated NeuroCap™ DeviceBrain Scientific Inc. announced the immediate release of the improved and updated NeuroCap™ device. NeuroCap satisfies the three criteria D&D Medical uses to select new technologies to represent: it provides a safer alternative for the patients and clinicians, it’s innovative and new, and it saves hospitals and patients money. Brain Scientific’s newly improved NeuroCap recently entered production for the company and its distributors to build stock and fulfill customer requests. The improvements to the NeuroCap include a proprietary gel with better conductivity, improved performance adhesive pads, a more conductive, precise ink formulation, and a base of modern blue PET material. Brain Scientific developed the NeuroCap to streamline EEG prep, testing and diagnosis. NeuroCap has 22 pre-gelled electrodes making it a suitable option for most clinical EEG tests, including routine EEGs that are often used for stroke and epilepsy patients. The fixed electrode placement is in accordance with the international 10-20 system. The Brain Scientific NeuroCap is an FDA 510k cleared, pre-gelled disposable EEG headset for clinical use. It allows any clinician to prepare a patient for an EEG exam in a fraction of the time normally spent applying individual electrodes. The NeuroCap can be used in nearly any environment, including rural hospitals, ambulances, private practices and athletic events, vastly expanding access to EEG testing. It is currently available in four sizes, including pediatric sizes.お知らせ • Nov 02Brain Scientific Appoints Daniel Cloutier as Chief Revenue OfficerBrain Scientific announced that Daniel Cloutier is joining the company as its chief revenue officer (CRO) in a move that will help propel the company forward on its mission to revolutionize the medical industry. Cloutier brings extensive experience and knowledge in sales strategy and global distribution. He founded LOK Corporation in 2011 after representing CAS Medical System (CASMED) for eight years as international sales director and launching the FORE-SIGHT cerebral oximetry internationally. Cloutier will lead Brain Scientific’s sales and marketing strategy, leveraging his experience in direct and indirect sales channels and deep relationships across distributors, research institutions and regulators in the medical technology space. Cloutier is also an advisory council member of the Indian Business Organization for Global Investments, a member of the board of directors for the Independent Medical Specialty Dealers Association and Brain Scientific, and a former board member of NeuroFrance Implants and Luminor Medical Technologies. He received his education from HEC Montréal.お知らせ • Aug 25Brain Scientific Announces CE Mark Approval for NeuroCap™ DeviceBrain Scientific Inc. announces receiving the Conformité Européenne (CE) Mark for the NeuroCap™. The CE mark confirms that Brain Scientific meets all European Medical Device Directive requirements to begin commercializing its innovative neurological devices across the European Continent and other CE mark geographies. Brain Scientific has developed two distinct devices to streamline EEG prep, testing, and diagnosis. NeuroCap™ has 22 pre-gelled electrodes making it a suitable option for most clinical EEG tests, including routine EEGs that are often used for stroke and epilepsy patients. The fixed electrode placement is in accordance with the international 10-20 system. NeuroEEG™ is a 21-channel amplifier that provides clinicians with the same quality as traditional EEG equipment. The NeuroCap™ is an FDA 510k cleared, pre-gelled disposable EEG headset for clinical use. The NeuroCap™ allows any clinician to prepare a patient for an EEG exam in a fraction of the time normally spent applying individual electrodes. The NeuroCap™ can be used in nearly any environment, including rural hospitals, ambulances, private practices, and athletic events, vastly expanding access to EEG testing. It is currently available in four sizes, including pediatric sizes.お知らせ • Aug 13Brain Scientific Inc. has filed an IPO in the amount of $12.075 million.Brain Scientific Inc. has filed an IPO in the amount of $12.075 million. Security Name: Units Security Type: Equity/Derivative Unit Transaction Features: New Market Listingお知らせ • Aug 05Manchester Management Company Engages in Discussions with Brain ScientificOn August 4, 2022, Manchester Management Company, LLC announced that it has been and might continue to be in contact with members of Brain Scientific Inc.'s management, the Company's Board of Directors, other significant shareholders and others regarding alternatives that the Company could employ to maximize shareholder value.お知らせ • Jul 20Brain Scientific Inc. announced that it has received $5.145 million in fundingOn July 19, 2022, Brain Scientific Inc. closed the transaction. On the same date, the company amended the terms of the transaction. The company raised $5,145,000 in the transaction. The transaction included participation from 11 investors.お知らせ • May 05Brain Scientific Announces its Novel Neurology Products Will be Presented to the NATO Center of Excellence for Military MedicineBrain Scientific announced that its novel neurology products will be presented to the NATO Center of Excellence for Military Medicine as an innovative and potentially life-saving tool for armed service personnel. Currently patients must await transportation to a hospital or clinic to receive EEG testing to determine brain injury or neurological conditions. Once there, they can wait hours or even overnight to see a specialized neurology technician. With Brain Scientific’s NeuroCap™ device, any field medic can record EEG data in remote locations, greatly expanding EEG accessibility. The disposable, lightweight, and easy-to-use NeuroCap can be a vital tool to field medics and other medical personnel wherever EEG testing is needed most.お知らせ • Feb 09Brain Scientific Inc. Announces Resignation of Mr. Todd Eckler as Chief Revenue Officer, Effective on February 11, 2022On February 7, 2022, Mr. Todd Eckler submitted to the board of directors of Brain Scientific Inc. his resignation from his position as Chief Revenue Officer of the company, effective February 11, 2022.お知らせ • Aug 17Brain Scientific Inc. announced delayed 10-Q filingOn 08/16/2021, Brain Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 17+ 1 more updateBrain Scientific Inc. announced that it expects to receive $5 million in fundingBrain Scientific Inc. (OTCPK:BRSF) announced that it has entered into a securities purchase agreement for the private placement of units for gross proceeds of $5 million on June 16, 2021. Each unit is convertible into a 10% convertible promissory note and a common stock purchase warrant. The promissory note will have a one year maturity date and common stock purchase warrants upon the terms and subject to the conditions of a separate securities purchase agreement. The transaction is expected to close on July 30, 2021. The transaction is subject to the closing conditions.お知らせ • May 18Brain Scientific Inc. announced delayed 10-Q filingOn 05/17/2021, Brain Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 03Brain Scientific Inc. announced delayed annual 10-K filingOn 04/01/2021, Brain Scientific Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 11Brain Scientific Announces FDA Clearance for Next-Gen NeuroCap™ EEG HeadsetBrain Scientific Inc. announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its next generation NeuroCap™ device. NeuroCap™ is an advanced Electroencephalogram (EEG) electrode array used to obtain rapid EEGs in routine clinical and research settings where recording of STAT EEGs is desired. NeuroCap™ is a disposable pre-gelled EEG headset with 22 electrodes and 19 active EEG channels located in accordance with the 10-20 system. Pre-gelled, fixed electrode locations eliminate time consuming tasks of head measurement and electrode placement. The cap is FDA-cleared to stay on a patient’s head for up to 4 hours. NeuroCap™ is compatible with most encephalographs on the market and can be applied in just 5 minutes. Brain Scientific wants to improve patient access to neurological care. The Company’s data implies that only 30% of U.S. hospitals have equipment for routine EEGs due to cost and space constraints. The global pandemic is still raging and some studies show [5] that more than 80% of hospitalized COVID-19 patients have neurological symptoms, which could require EEG testing. Additionally, there is an urgent need to limit contact between EEG technicians and patients.お知らせ • Feb 18Ehave Inc. and Brain Scientific Inc. Sign Memorandum of UnderstandingEhave, Inc. announced it has entered into a Memorandum of Understanding with Brain Scientific Inc. that will allow the two companies to leverage both data and AI to correlate biomarkers for the identification of chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD and schizophrenia. The terms of the MoU call for Ehave and Brain Scientific to collaborate to exploit graph based AI, linked data protocols with respect to such AI, and leverage such data and AI to develop neural net algorithms. As an initial matter, one purpose of the neural net algorithm would be to upload already trained neuronet into a specialized chip that Brain Scientific is developing into a temporary E-Tattoo. As part of the MoU, Ehave would integrate Brain Scientific's NeuroCap and NeuroEEG to acquire data from patients in real time, or put such data into a cloud. Ehave could also seek to deploy NeuroCap and NeuroEEG in clinical settings with Ehave’s partner healthcare providers, such as psychiatrists, psychologists, psychotherapists and general practitioners. This will allow Ehave to capture the data around the electrophysiological changes in brain pre, mid and post psychedelic drug administration, and possibly build or partner with a functional lab to be equipped with NeuroCap and NeuroEEG devices to conduct market studies and collect data on various brain related physiological and mental disorders. These market studies and data collection activities are likely to begin in Australia and could be implemented in other parts of the world where Ehave operates. This same functional lab can be used to study consumer behavior and psychology in markets Ehave operates for further commercialization of Ehave’s data and technologies. Brain Scientific is seeking to improve neurology by modernizing the brain diagnostic market with its technology. As part of the MoU, Brain Scientific would provide its proprietary data signal acquisition devices, NeuroCap and NeuroEEG, for the Ehave platform. Brain Scientific will also provide the training and support needed to operate the installed equipment, the necessary software and hardware for the development of the technology and products, and will develop and validate products within three months of receiving any specifications from Ehave. All data from any transactions contemplated by the MoU will be jointly owned by both Ehave and Brain Scientific. Ehave will cover the cost of testing and certification for products developed under this MoU and will receive full rights to all related intellectual property, including the right to sell and distribute any such products, on a 50/50 split basis after all expenses, including research and development. The transactions contemplated by the MoU are subject to the negotiation, execution and delivery by the parties of definitive final agreements.お知らせ • Jan 22Brain Scientific Inc. Unveils New Initiative to Develop Brain E-Tattoo Device for the Brain Diagnostics MarketBrain Scientific Inc. has announced that it has commenced development of its proposed Brain E-Tattoo device for the brain diagnostics market, which is expected to feature a temporary implanted or imprinted minimally invasive, subcutaneous graphene electrode paired with a micro EEG. The proposed device is expected to allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions such as epilepsy, Alzheimer’s disease, stroke, and other brain disorders. Brain Scientific is working on safety testing, general proof of concept testing and performance testing for the Brain E-Tattoo device, prior to FDA submission. The company’s proposed Brain E-Tattoo device is being designed to monitor brain wave activity beyond the clinical setting, with no or minimal impact to the patient’s daily life. The Brain E-Tattoo’s graphene-based electrodes would be connected to the micro EEG clipped behind the ear, which processes the signals from the sensors and wirelessly transfers data to a cloud application. Each patient’s data is secured in the cloud where Brain Scientific’s artificial intelligence performs continuous analysis. Brain Scientific expects that the device will provide researchers with an affordable option to monitor, study, and continue research for numerous neurological disorders, including epilepsy, one of the most common chronic brain diseases. For epileptic patients and others facing neurological diseases, Brain Scientific hopes that the continued analysis and AI prediction will lead to a better understanding of neurological disorders.お知らせ • Dec 19Brain Scientific to Enter the U.S. Pediatric Market with NeuroCap™ for ChildrenBrain Scientific Inc. has announced its next generation disposable EEG cap, NeuroCap™, will now be available to the pediatric market across the U.S. The product launch allows Brain Scientific to bring faster, more efficient, and sanitary testing procedures to pediatric professionals in the United States. The child-size NeuroCap headset will assist clinicians in overcoming the common obstacles when conducting an electroencephalogram (EEG), including measuring and marking the patient’s head, and conducting required sanitation protocols afterwards. The NeuroCap for children is designed to address the need for comfort, speed, and reliability within the pediatric population. The disposable NeuroCap is a pre-gelled hospital-grade EEG headset that can be applied easily and quickly by any member of a clinical staff. Each headset features 19 active EEG channels and 22 electrodes located in accordance with 10-20 international system. The comfortable design and prompt test results make the NeuroCap an ideal option for pediatric patients in emergency rooms, intensive care units, clinics, and other treatment centers that administer EEG’s on children. The need for EEG testing among children stems from various underlying symptoms and conditions, including seizures, sleep troubles, brain infections, and neurological disorders. Brain Scientific is working to help better equip healthcare facilities nationwide with its easy-to-use solutions for children ranging from 2 to 18 years old, while providing convenience and comfort. The expansion into the pediatric market will also work to make a positive impact on pediatric epilepsy patients, as epilepsy has become one of the most common neurological disorders seen in children as noted by the Pediatrics in Review Journal. Additionally, another common use for children’s EEG testing extends to those experiencing symptoms of ADHD. Children diagnosed with ADHD has increased 42% in the U.S. over the past decade, according to Child and Adolescent Psychiatry. EEG testing is one of the key tools in the diagnosis process to identify disorders and to begin to proactively seek treatment options. The Company expects that the pediatric NeuroCap will provide a meaningful solution to ensure these patient populations and others get access to testing that is both comfortable and stress-free. Brain Scientific continues to make strides within Neurology by modernizing the brain diagnostic market with its cutting-edge technology. The pediatric NeuroCap is expected to be available to clinicians across the United States early next year and joins Brain Scientific’s proprietary lineup of diagnostic devices.お知らせ • Dec 03Brain Scientific Files Patent Application for New Long-Term Monitoring EEG CapBrain Scientific Inc. has filed a provisional patent application in the United States Patent and Trademark Office (“USPTO”) entitled, “FULL HEAD APPARATUS AND ELECTRODES FOR CONDUCTING ELECTROENCEPHALOGRAPHY.” During EEG testing electrodes are put to the person’s head by either a cap application or placement of each electrode. The latter method is time consuming and requires a trained technician. Reusable caps and electrodes need cleaning and adding gel - a lengthy procedure that can also transmit germs. Both methods can lead to recording incorrect signals if the person moves during the test. Additionally, when an electrode cap is used for EEG, customizing it to fit users remains a challenge due to the various head sizes. Disposable EEG caps address this problem but they can only be provided with pre-set sizes. Traditionally, EEG tests have been useful in helping diagnose conditions relating to brain injuries, such as seizures, strokes, brain tumors, Alzheimer’s disease and certain psychoses. Recent studies show more than 80% of hospitalized COVID-19 patients have neurological symptoms, which could require EEG testing. Also, Brain Scientific estimates that approximately 5 million patients in U.S. emergency departments and ICUs are subject to seizures and could benefit from routine EEG tests. Additionally, EEG systems have gone through evolution to become an integral part of modern applications, such as brain computer interface for controlling electronic devices, neurofeedback activities, electronic sports (e-sports), health and wellness parameter collection, virtual and augmented reality, and sleep pattern evaluations.お知らせ • Nov 18Brain Scientific Inc. Has Enters into an Agreement with AFINA s.r.oBrain Scientific Inc. has entered into an agreement with AFINA s.r.o. The agreement specifies that AFINA will act as an authorized representative for Brain Scientific in the European Union and assist with registering Brain Scientific’s advanced EEG solutions in 32 countries in the European market. The next generation NeuroCap by Brain Scientific is a hospital-grade disposable EEG headset featuring 22 electrodes and 19 active EEG channels. The pre-gelled disposable cap removes the time-consuming task of placing electrodes and measuring the patient's head, which gives both neurological technicians and clinical staffers the ability to provide immediate care. The NeuroCap works alongside Brain Scientific’s NeuroEEG™, an amplifier device to initiate the EEG studies in less than five minutes. In the EU, neurological disorders are ranked third after cardiovascular diseases and cancers, representing 13.3% of total cases and 19.5% of total deaths. Stroke, dementias and headache are the three most common causes of DALYs - the Disability Adjusted Life Years in the EU, as measured by the World Health Organization.お知らせ • Nov 17Brain Scientific Inc. announced delayed 10-Q filingOn 11/16/2020, Brain Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 14Brain Scientific Inc. Seeks FDA Approval of Next-Gen NeuroCap™ EEG Cap Amidst New Data on Neurological Problems in COVID PatientsBrain Scientific Inc. has submitted a premarket 510(k) application to the United States Food and Drug Administration for its next generation NeuroCap device. NeuroCap is an advanced Electroencephalogram (EEG) electrode array used to obtain rapid EEGs in hospitals, clinics and rural areas where medical resources may be limited. NeuroCap™ can be applied in just 5 minutes and changed with each patient, removing the need to disinfect between uses. It is compatible with 3rd party amplifiers of EEG signals. Before applying for the FDA approval, Brain Scientific has evaluated the device for safety and performance according to ISO and ANSI/AAMI EC12: 2000 Disposable ECG electrodes standards. The global pandemic is still raging, and new studies show more than 80% of hospitalized COVID-19 patients have neurological symptoms, which could require EEG testing. Additionally, there is an urgent need to limit contact between EEG technicians and patients in emergency rooms, ICUs, and clinical research facilities. The company believes that disposable EEG headsets represent a large market opportunity, estimating that approximately 5 million patients in US emergency departments and ICUs are subject to seizures and could benefit from routine EEG tests. The company’s data implies that one in 26 people in the US will be diagnosed with epilepsy at some point in their life, while only 254 of 6,210 US hospitals are Level 4 epilepsy centers with 24/7 EEG services.お知らせ • Sep 30Brain Scientific Inc. announced that it expects to receive $0.6 million in funding from Auctus Fund Management, LLCBrain Scientific Inc. (OTCPK:BRSF) announced that it has entered into securities purchase agreement with Auctus Fund, LLC, a fund managed by Auctus Fund Management, LLC for a private placement of promissory notes for $600,000 on September 22, 2020. The company will also issue two stock purchase warrants such as warrant A and warrant B in the transaction. The company allowing the investor to purchase an aggregate of 1,411,764 shares of the company’s common stock with warrant A being a commitment fee of 705,882 shares of common stock, and warrant B being fully earned upon issuance as an additional commitment fee of 705,882 shares of common stock, provide that warrant B is returnable to the company upon the repayment of the note. The warrants will be exercisable into common shares at a price of $1.28 per share on pr after three-year anniversary. The notes bear an fixed coupon rate of 12% per annum and will be due on September 22, 2021. A lump-sum interest payment for one year shall be immediately due on announced date and shall be added to the principal balance and payable on the maturity date or upon acceleration or by prepayment or otherwise, notwithstanding the number of days which the principal is outstanding. Principal payments shall be made in six installments each in the amount of $100,000 commencing 180 days following the announcement date and continuing thereafter each 30 days for 5 months. Any amount of principal or interest on this note which is not paid when due shall bear interest at the rate of the lesser of 24% per annum and the maximum amount permitted under law from the due date thereof until the same is paid. The investor have a right to convert the notes into common stock in case of default. The company will close the deal in two tranche. The company will receive $100,000 on September 23, 2020 and remaining $500,000 on October 19, 2020. The company will issue securities pursuant to exemption provided under Regulation Dお知らせ • Sep 24Brain Scientific Inc. Announces Resignation Vadim Sakharov as Member of the Board of Directors, President and Chief Technology OfficerOn September 22, 2020, Vadim Sakharov, a member of the Board of Directors of Brain Scientific Inc. and its President and Chief Technology Officer, resigned from the Board and from all of his positions with the Company, effective immediately. The Company intends to continue to consult with Mr. Sakharov on terms to be determined.お知らせ • Sep 04Brain Scientific Inc. announced that it has received $0.1425 million in funding from Diamond Investment Group II LLCBrain Scientific Inc. (OTCPK:BRSF) announced that it has entered into a securities purchase agreement with Diamond Investment Group II LLC for a private placement of an 8% convertible redeemable note for gross proceeds of $150,000 on September 1, 2020. The par value of the note is $157,500, which is issued at a discount of $7,500 in the transaction. The note is convertible into common shares of the company. The conversion price shall be equal to 60% of the lowest closing bid price for the common stock for the fifteen prior trading day period. The company shall have the right to pre-pay the entire remaining principal amount of the note from the issuance date until 180 days after the issuance date, upon 3 days’ notice to the investor, subject to the pre-payment terms. The note will mature on September 1, 2021. The note issued in the transaction is restricted in nature.お知らせ • Aug 18+ 1 more updateBrain Scientific Inc. announced delayed 10-Q filingOn 08/17/2020, Brain Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.株主還元BRSFUS Medical EquipmentUS 市場7D0%3.0%-0.8%1Yn/a-18.3%27.1%株主還元を見る業界別リターン: BRSFがUS Medical Equipment業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: BRSF US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is BRSF's price volatile compared to industry and market?BRSF volatilityBRSF Average Weekly Movementn/aMedical Equipment Industry Average Movement8.6%Market Average Movement7.2%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%安定した株価: BRSFの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のBRSFのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2013n/aHassan Kotobn/aブレイン・サイエンティフィック社は医療技術企業で、米国および海外で神経学および運動製品を提供している。同社は、従来の脳波（EEG）システムの既存の問題点を解決するために設計された電極回路内蔵の使い捨てソフトレイヤーキャップ「ニューロキャップ」、ニューロキャップから取り込んだデータを保存・分析するために使用するニューロEEGアンプとデスクトップソフトウェア、圧電モーターを提供している。同社はまた、患者や臨床データにアクセスして患者の状態を遠隔評価できるNeuroHubも開発している。同社のNeuroCapおよびNeuroEEG製品は、神経科クリニック、都市部や地方のED、ICU、急患診療所、老人ホームや福祉施設、スポーツ施設、遠隔臨床研究、その他の環境での脳波記録に使用できる。ブレインサイエンティフィック社は2013年に設立され、フロリダ州サラソタに本社を置いている。もっと見るBrain Scientific Inc. 基礎のまとめBrain Scientific の収益と売上を時価総額と比較するとどうか。BRSF 基礎統計学時価総額US$745.00収益（TTM）-US$12.34m売上高(TTM)US$214.56k0.0xP/Sレシオ0.0xPER（株価収益率BRSF は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BRSF 損益計算書（TTM）収益US$214.56k売上原価US$160.24k売上総利益US$54.33kその他の費用US$12.40m収益-US$12.34m直近の収益報告Dec 31, 2022次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%BRSF の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 20:36終値2026/05/13 00:00収益2022/12/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Brain Scientific Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 04Brain Scientific Inc. Announces the Resignation of Fred Anthony as Chief Technology OfficerOn December 29, 2022, Mr. Fred Anthony submitted to the board of directors of Brain Scientific Inc. (the “Company”) his resignation from his position as Chief Technology Officer of the Company, effective December 30, 2022.
お知らせ • Dec 03Brain Scientific Appoints Kevin Winterfield as Vice President of Marketing and CommunicationBrain Scientific announced the appointment of Kevin Winterfield as Vice President of Marketing and Communications to accelerate Brain Scientific's strategic growth plan heading into the new year. Kevin Winterfield joins the Brain Scientific team as vice president of marketing and communications. He brings a wealth of marketing and communications experience in the B2B technology space. Winterfield has designed and led successful campaigns with IBM, Consumer Reports, TeamKCI and Bantam Tools to develop brands across identity creation, messaging, launch and sales. He also worked as an EEG and evoked potential technician early in his career and knows firsthand that the wearables market is ripe for rapid innovation. Winterfield will work hand-in-hand with Daniel Cloutier, who recently joined the Brain Scientific team as chief revenue officer.
お知らせ • Nov 16Brain Scientific Inc. Announces Release of Improved and Updated NeuroCap™ DeviceBrain Scientific Inc. announced the immediate release of the improved and updated NeuroCap™ device. NeuroCap satisfies the three criteria D&D Medical uses to select new technologies to represent: it provides a safer alternative for the patients and clinicians, it’s innovative and new, and it saves hospitals and patients money. Brain Scientific’s newly improved NeuroCap recently entered production for the company and its distributors to build stock and fulfill customer requests. The improvements to the NeuroCap include a proprietary gel with better conductivity, improved performance adhesive pads, a more conductive, precise ink formulation, and a base of modern blue PET material. Brain Scientific developed the NeuroCap to streamline EEG prep, testing and diagnosis. NeuroCap has 22 pre-gelled electrodes making it a suitable option for most clinical EEG tests, including routine EEGs that are often used for stroke and epilepsy patients. The fixed electrode placement is in accordance with the international 10-20 system. The Brain Scientific NeuroCap is an FDA 510k cleared, pre-gelled disposable EEG headset for clinical use. It allows any clinician to prepare a patient for an EEG exam in a fraction of the time normally spent applying individual electrodes. The NeuroCap can be used in nearly any environment, including rural hospitals, ambulances, private practices and athletic events, vastly expanding access to EEG testing. It is currently available in four sizes, including pediatric sizes.
お知らせ • Nov 02Brain Scientific Appoints Daniel Cloutier as Chief Revenue OfficerBrain Scientific announced that Daniel Cloutier is joining the company as its chief revenue officer (CRO) in a move that will help propel the company forward on its mission to revolutionize the medical industry. Cloutier brings extensive experience and knowledge in sales strategy and global distribution. He founded LOK Corporation in 2011 after representing CAS Medical System (CASMED) for eight years as international sales director and launching the FORE-SIGHT cerebral oximetry internationally. Cloutier will lead Brain Scientific’s sales and marketing strategy, leveraging his experience in direct and indirect sales channels and deep relationships across distributors, research institutions and regulators in the medical technology space. Cloutier is also an advisory council member of the Indian Business Organization for Global Investments, a member of the board of directors for the Independent Medical Specialty Dealers Association and Brain Scientific, and a former board member of NeuroFrance Implants and Luminor Medical Technologies. He received his education from HEC Montréal.
お知らせ • Aug 25Brain Scientific Announces CE Mark Approval for NeuroCap™ DeviceBrain Scientific Inc. announces receiving the Conformité Européenne (CE) Mark for the NeuroCap™. The CE mark confirms that Brain Scientific meets all European Medical Device Directive requirements to begin commercializing its innovative neurological devices across the European Continent and other CE mark geographies. Brain Scientific has developed two distinct devices to streamline EEG prep, testing, and diagnosis. NeuroCap™ has 22 pre-gelled electrodes making it a suitable option for most clinical EEG tests, including routine EEGs that are often used for stroke and epilepsy patients. The fixed electrode placement is in accordance with the international 10-20 system. NeuroEEG™ is a 21-channel amplifier that provides clinicians with the same quality as traditional EEG equipment. The NeuroCap™ is an FDA 510k cleared, pre-gelled disposable EEG headset for clinical use. The NeuroCap™ allows any clinician to prepare a patient for an EEG exam in a fraction of the time normally spent applying individual electrodes. The NeuroCap™ can be used in nearly any environment, including rural hospitals, ambulances, private practices, and athletic events, vastly expanding access to EEG testing. It is currently available in four sizes, including pediatric sizes.
お知らせ • Aug 13Brain Scientific Inc. has filed an IPO in the amount of $12.075 million.Brain Scientific Inc. has filed an IPO in the amount of $12.075 million. Security Name: Units Security Type: Equity/Derivative Unit Transaction Features: New Market Listing
お知らせ • Jan 04Brain Scientific Inc. Announces the Resignation of Fred Anthony as Chief Technology OfficerOn December 29, 2022, Mr. Fred Anthony submitted to the board of directors of Brain Scientific Inc. (the “Company”) his resignation from his position as Chief Technology Officer of the Company, effective December 30, 2022.
お知らせ • Dec 03Brain Scientific Appoints Kevin Winterfield as Vice President of Marketing and CommunicationBrain Scientific announced the appointment of Kevin Winterfield as Vice President of Marketing and Communications to accelerate Brain Scientific's strategic growth plan heading into the new year. Kevin Winterfield joins the Brain Scientific team as vice president of marketing and communications. He brings a wealth of marketing and communications experience in the B2B technology space. Winterfield has designed and led successful campaigns with IBM, Consumer Reports, TeamKCI and Bantam Tools to develop brands across identity creation, messaging, launch and sales. He also worked as an EEG and evoked potential technician early in his career and knows firsthand that the wearables market is ripe for rapid innovation. Winterfield will work hand-in-hand with Daniel Cloutier, who recently joined the Brain Scientific team as chief revenue officer.
お知らせ • Nov 16Brain Scientific Inc. Announces Release of Improved and Updated NeuroCap™ DeviceBrain Scientific Inc. announced the immediate release of the improved and updated NeuroCap™ device. NeuroCap satisfies the three criteria D&D Medical uses to select new technologies to represent: it provides a safer alternative for the patients and clinicians, it’s innovative and new, and it saves hospitals and patients money. Brain Scientific’s newly improved NeuroCap recently entered production for the company and its distributors to build stock and fulfill customer requests. The improvements to the NeuroCap include a proprietary gel with better conductivity, improved performance adhesive pads, a more conductive, precise ink formulation, and a base of modern blue PET material. Brain Scientific developed the NeuroCap to streamline EEG prep, testing and diagnosis. NeuroCap has 22 pre-gelled electrodes making it a suitable option for most clinical EEG tests, including routine EEGs that are often used for stroke and epilepsy patients. The fixed electrode placement is in accordance with the international 10-20 system. The Brain Scientific NeuroCap is an FDA 510k cleared, pre-gelled disposable EEG headset for clinical use. It allows any clinician to prepare a patient for an EEG exam in a fraction of the time normally spent applying individual electrodes. The NeuroCap can be used in nearly any environment, including rural hospitals, ambulances, private practices and athletic events, vastly expanding access to EEG testing. It is currently available in four sizes, including pediatric sizes.
お知らせ • Nov 02Brain Scientific Appoints Daniel Cloutier as Chief Revenue OfficerBrain Scientific announced that Daniel Cloutier is joining the company as its chief revenue officer (CRO) in a move that will help propel the company forward on its mission to revolutionize the medical industry. Cloutier brings extensive experience and knowledge in sales strategy and global distribution. He founded LOK Corporation in 2011 after representing CAS Medical System (CASMED) for eight years as international sales director and launching the FORE-SIGHT cerebral oximetry internationally. Cloutier will lead Brain Scientific’s sales and marketing strategy, leveraging his experience in direct and indirect sales channels and deep relationships across distributors, research institutions and regulators in the medical technology space. Cloutier is also an advisory council member of the Indian Business Organization for Global Investments, a member of the board of directors for the Independent Medical Specialty Dealers Association and Brain Scientific, and a former board member of NeuroFrance Implants and Luminor Medical Technologies. He received his education from HEC Montréal.
お知らせ • Aug 25Brain Scientific Announces CE Mark Approval for NeuroCap™ DeviceBrain Scientific Inc. announces receiving the Conformité Européenne (CE) Mark for the NeuroCap™. The CE mark confirms that Brain Scientific meets all European Medical Device Directive requirements to begin commercializing its innovative neurological devices across the European Continent and other CE mark geographies. Brain Scientific has developed two distinct devices to streamline EEG prep, testing, and diagnosis. NeuroCap™ has 22 pre-gelled electrodes making it a suitable option for most clinical EEG tests, including routine EEGs that are often used for stroke and epilepsy patients. The fixed electrode placement is in accordance with the international 10-20 system. NeuroEEG™ is a 21-channel amplifier that provides clinicians with the same quality as traditional EEG equipment. The NeuroCap™ is an FDA 510k cleared, pre-gelled disposable EEG headset for clinical use. The NeuroCap™ allows any clinician to prepare a patient for an EEG exam in a fraction of the time normally spent applying individual electrodes. The NeuroCap™ can be used in nearly any environment, including rural hospitals, ambulances, private practices, and athletic events, vastly expanding access to EEG testing. It is currently available in four sizes, including pediatric sizes.
お知らせ • Aug 13Brain Scientific Inc. has filed an IPO in the amount of $12.075 million.Brain Scientific Inc. has filed an IPO in the amount of $12.075 million. Security Name: Units Security Type: Equity/Derivative Unit Transaction Features: New Market Listing
お知らせ • Aug 05Manchester Management Company Engages in Discussions with Brain ScientificOn August 4, 2022, Manchester Management Company, LLC announced that it has been and might continue to be in contact with members of Brain Scientific Inc.'s management, the Company's Board of Directors, other significant shareholders and others regarding alternatives that the Company could employ to maximize shareholder value.
お知らせ • Jul 20Brain Scientific Inc. announced that it has received $5.145 million in fundingOn July 19, 2022, Brain Scientific Inc. closed the transaction. On the same date, the company amended the terms of the transaction. The company raised $5,145,000 in the transaction. The transaction included participation from 11 investors.
お知らせ • May 05Brain Scientific Announces its Novel Neurology Products Will be Presented to the NATO Center of Excellence for Military MedicineBrain Scientific announced that its novel neurology products will be presented to the NATO Center of Excellence for Military Medicine as an innovative and potentially life-saving tool for armed service personnel. Currently patients must await transportation to a hospital or clinic to receive EEG testing to determine brain injury or neurological conditions. Once there, they can wait hours or even overnight to see a specialized neurology technician. With Brain Scientific’s NeuroCap™ device, any field medic can record EEG data in remote locations, greatly expanding EEG accessibility. The disposable, lightweight, and easy-to-use NeuroCap can be a vital tool to field medics and other medical personnel wherever EEG testing is needed most.
お知らせ • Feb 09Brain Scientific Inc. Announces Resignation of Mr. Todd Eckler as Chief Revenue Officer, Effective on February 11, 2022On February 7, 2022, Mr. Todd Eckler submitted to the board of directors of Brain Scientific Inc. his resignation from his position as Chief Revenue Officer of the company, effective February 11, 2022.
お知らせ • Aug 17Brain Scientific Inc. announced delayed 10-Q filingOn 08/16/2021, Brain Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 17+ 1 more updateBrain Scientific Inc. announced that it expects to receive $5 million in fundingBrain Scientific Inc. (OTCPK:BRSF) announced that it has entered into a securities purchase agreement for the private placement of units for gross proceeds of $5 million on June 16, 2021. Each unit is convertible into a 10% convertible promissory note and a common stock purchase warrant. The promissory note will have a one year maturity date and common stock purchase warrants upon the terms and subject to the conditions of a separate securities purchase agreement. The transaction is expected to close on July 30, 2021. The transaction is subject to the closing conditions.
お知らせ • May 18Brain Scientific Inc. announced delayed 10-Q filingOn 05/17/2021, Brain Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 03Brain Scientific Inc. announced delayed annual 10-K filingOn 04/01/2021, Brain Scientific Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 11Brain Scientific Announces FDA Clearance for Next-Gen NeuroCap™ EEG HeadsetBrain Scientific Inc. announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its next generation NeuroCap™ device. NeuroCap™ is an advanced Electroencephalogram (EEG) electrode array used to obtain rapid EEGs in routine clinical and research settings where recording of STAT EEGs is desired. NeuroCap™ is a disposable pre-gelled EEG headset with 22 electrodes and 19 active EEG channels located in accordance with the 10-20 system. Pre-gelled, fixed electrode locations eliminate time consuming tasks of head measurement and electrode placement. The cap is FDA-cleared to stay on a patient’s head for up to 4 hours. NeuroCap™ is compatible with most encephalographs on the market and can be applied in just 5 minutes. Brain Scientific wants to improve patient access to neurological care. The Company’s data implies that only 30% of U.S. hospitals have equipment for routine EEGs due to cost and space constraints. The global pandemic is still raging and some studies show [5] that more than 80% of hospitalized COVID-19 patients have neurological symptoms, which could require EEG testing. Additionally, there is an urgent need to limit contact between EEG technicians and patients.
お知らせ • Feb 18Ehave Inc. and Brain Scientific Inc. Sign Memorandum of UnderstandingEhave, Inc. announced it has entered into a Memorandum of Understanding with Brain Scientific Inc. that will allow the two companies to leverage both data and AI to correlate biomarkers for the identification of chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD and schizophrenia. The terms of the MoU call for Ehave and Brain Scientific to collaborate to exploit graph based AI, linked data protocols with respect to such AI, and leverage such data and AI to develop neural net algorithms. As an initial matter, one purpose of the neural net algorithm would be to upload already trained neuronet into a specialized chip that Brain Scientific is developing into a temporary E-Tattoo. As part of the MoU, Ehave would integrate Brain Scientific's NeuroCap and NeuroEEG to acquire data from patients in real time, or put such data into a cloud. Ehave could also seek to deploy NeuroCap and NeuroEEG in clinical settings with Ehave’s partner healthcare providers, such as psychiatrists, psychologists, psychotherapists and general practitioners. This will allow Ehave to capture the data around the electrophysiological changes in brain pre, mid and post psychedelic drug administration, and possibly build or partner with a functional lab to be equipped with NeuroCap and NeuroEEG devices to conduct market studies and collect data on various brain related physiological and mental disorders. These market studies and data collection activities are likely to begin in Australia and could be implemented in other parts of the world where Ehave operates. This same functional lab can be used to study consumer behavior and psychology in markets Ehave operates for further commercialization of Ehave’s data and technologies. Brain Scientific is seeking to improve neurology by modernizing the brain diagnostic market with its technology. As part of the MoU, Brain Scientific would provide its proprietary data signal acquisition devices, NeuroCap and NeuroEEG, for the Ehave platform. Brain Scientific will also provide the training and support needed to operate the installed equipment, the necessary software and hardware for the development of the technology and products, and will develop and validate products within three months of receiving any specifications from Ehave. All data from any transactions contemplated by the MoU will be jointly owned by both Ehave and Brain Scientific. Ehave will cover the cost of testing and certification for products developed under this MoU and will receive full rights to all related intellectual property, including the right to sell and distribute any such products, on a 50/50 split basis after all expenses, including research and development. The transactions contemplated by the MoU are subject to the negotiation, execution and delivery by the parties of definitive final agreements.
お知らせ • Jan 22Brain Scientific Inc. Unveils New Initiative to Develop Brain E-Tattoo Device for the Brain Diagnostics MarketBrain Scientific Inc. has announced that it has commenced development of its proposed Brain E-Tattoo device for the brain diagnostics market, which is expected to feature a temporary implanted or imprinted minimally invasive, subcutaneous graphene electrode paired with a micro EEG. The proposed device is expected to allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions such as epilepsy, Alzheimer’s disease, stroke, and other brain disorders. Brain Scientific is working on safety testing, general proof of concept testing and performance testing for the Brain E-Tattoo device, prior to FDA submission. The company’s proposed Brain E-Tattoo device is being designed to monitor brain wave activity beyond the clinical setting, with no or minimal impact to the patient’s daily life. The Brain E-Tattoo’s graphene-based electrodes would be connected to the micro EEG clipped behind the ear, which processes the signals from the sensors and wirelessly transfers data to a cloud application. Each patient’s data is secured in the cloud where Brain Scientific’s artificial intelligence performs continuous analysis. Brain Scientific expects that the device will provide researchers with an affordable option to monitor, study, and continue research for numerous neurological disorders, including epilepsy, one of the most common chronic brain diseases. For epileptic patients and others facing neurological diseases, Brain Scientific hopes that the continued analysis and AI prediction will lead to a better understanding of neurological disorders.
お知らせ • Dec 19Brain Scientific to Enter the U.S. Pediatric Market with NeuroCap™ for ChildrenBrain Scientific Inc. has announced its next generation disposable EEG cap, NeuroCap™, will now be available to the pediatric market across the U.S. The product launch allows Brain Scientific to bring faster, more efficient, and sanitary testing procedures to pediatric professionals in the United States. The child-size NeuroCap headset will assist clinicians in overcoming the common obstacles when conducting an electroencephalogram (EEG), including measuring and marking the patient’s head, and conducting required sanitation protocols afterwards. The NeuroCap for children is designed to address the need for comfort, speed, and reliability within the pediatric population. The disposable NeuroCap is a pre-gelled hospital-grade EEG headset that can be applied easily and quickly by any member of a clinical staff. Each headset features 19 active EEG channels and 22 electrodes located in accordance with 10-20 international system. The comfortable design and prompt test results make the NeuroCap an ideal option for pediatric patients in emergency rooms, intensive care units, clinics, and other treatment centers that administer EEG’s on children. The need for EEG testing among children stems from various underlying symptoms and conditions, including seizures, sleep troubles, brain infections, and neurological disorders. Brain Scientific is working to help better equip healthcare facilities nationwide with its easy-to-use solutions for children ranging from 2 to 18 years old, while providing convenience and comfort. The expansion into the pediatric market will also work to make a positive impact on pediatric epilepsy patients, as epilepsy has become one of the most common neurological disorders seen in children as noted by the Pediatrics in Review Journal. Additionally, another common use for children’s EEG testing extends to those experiencing symptoms of ADHD. Children diagnosed with ADHD has increased 42% in the U.S. over the past decade, according to Child and Adolescent Psychiatry. EEG testing is one of the key tools in the diagnosis process to identify disorders and to begin to proactively seek treatment options. The Company expects that the pediatric NeuroCap will provide a meaningful solution to ensure these patient populations and others get access to testing that is both comfortable and stress-free. Brain Scientific continues to make strides within Neurology by modernizing the brain diagnostic market with its cutting-edge technology. The pediatric NeuroCap is expected to be available to clinicians across the United States early next year and joins Brain Scientific’s proprietary lineup of diagnostic devices.
お知らせ • Dec 03Brain Scientific Files Patent Application for New Long-Term Monitoring EEG CapBrain Scientific Inc. has filed a provisional patent application in the United States Patent and Trademark Office (“USPTO”) entitled, “FULL HEAD APPARATUS AND ELECTRODES FOR CONDUCTING ELECTROENCEPHALOGRAPHY.” During EEG testing electrodes are put to the person’s head by either a cap application or placement of each electrode. The latter method is time consuming and requires a trained technician. Reusable caps and electrodes need cleaning and adding gel - a lengthy procedure that can also transmit germs. Both methods can lead to recording incorrect signals if the person moves during the test. Additionally, when an electrode cap is used for EEG, customizing it to fit users remains a challenge due to the various head sizes. Disposable EEG caps address this problem but they can only be provided with pre-set sizes. Traditionally, EEG tests have been useful in helping diagnose conditions relating to brain injuries, such as seizures, strokes, brain tumors, Alzheimer’s disease and certain psychoses. Recent studies show more than 80% of hospitalized COVID-19 patients have neurological symptoms, which could require EEG testing. Also, Brain Scientific estimates that approximately 5 million patients in U.S. emergency departments and ICUs are subject to seizures and could benefit from routine EEG tests. Additionally, EEG systems have gone through evolution to become an integral part of modern applications, such as brain computer interface for controlling electronic devices, neurofeedback activities, electronic sports (e-sports), health and wellness parameter collection, virtual and augmented reality, and sleep pattern evaluations.
お知らせ • Nov 18Brain Scientific Inc. Has Enters into an Agreement with AFINA s.r.oBrain Scientific Inc. has entered into an agreement with AFINA s.r.o. The agreement specifies that AFINA will act as an authorized representative for Brain Scientific in the European Union and assist with registering Brain Scientific’s advanced EEG solutions in 32 countries in the European market. The next generation NeuroCap by Brain Scientific is a hospital-grade disposable EEG headset featuring 22 electrodes and 19 active EEG channels. The pre-gelled disposable cap removes the time-consuming task of placing electrodes and measuring the patient's head, which gives both neurological technicians and clinical staffers the ability to provide immediate care. The NeuroCap works alongside Brain Scientific’s NeuroEEG™, an amplifier device to initiate the EEG studies in less than five minutes. In the EU, neurological disorders are ranked third after cardiovascular diseases and cancers, representing 13.3% of total cases and 19.5% of total deaths. Stroke, dementias and headache are the three most common causes of DALYs - the Disability Adjusted Life Years in the EU, as measured by the World Health Organization.
お知らせ • Nov 17Brain Scientific Inc. announced delayed 10-Q filingOn 11/16/2020, Brain Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 14Brain Scientific Inc. Seeks FDA Approval of Next-Gen NeuroCap™ EEG Cap Amidst New Data on Neurological Problems in COVID PatientsBrain Scientific Inc. has submitted a premarket 510(k) application to the United States Food and Drug Administration for its next generation NeuroCap device. NeuroCap is an advanced Electroencephalogram (EEG) electrode array used to obtain rapid EEGs in hospitals, clinics and rural areas where medical resources may be limited. NeuroCap™ can be applied in just 5 minutes and changed with each patient, removing the need to disinfect between uses. It is compatible with 3rd party amplifiers of EEG signals. Before applying for the FDA approval, Brain Scientific has evaluated the device for safety and performance according to ISO and ANSI/AAMI EC12: 2000 Disposable ECG electrodes standards. The global pandemic is still raging, and new studies show more than 80% of hospitalized COVID-19 patients have neurological symptoms, which could require EEG testing. Additionally, there is an urgent need to limit contact between EEG technicians and patients in emergency rooms, ICUs, and clinical research facilities. The company believes that disposable EEG headsets represent a large market opportunity, estimating that approximately 5 million patients in US emergency departments and ICUs are subject to seizures and could benefit from routine EEG tests. The company’s data implies that one in 26 people in the US will be diagnosed with epilepsy at some point in their life, while only 254 of 6,210 US hospitals are Level 4 epilepsy centers with 24/7 EEG services.
お知らせ • Sep 30Brain Scientific Inc. announced that it expects to receive $0.6 million in funding from Auctus Fund Management, LLCBrain Scientific Inc. (OTCPK:BRSF) announced that it has entered into securities purchase agreement with Auctus Fund, LLC, a fund managed by Auctus Fund Management, LLC for a private placement of promissory notes for $600,000 on September 22, 2020. The company will also issue two stock purchase warrants such as warrant A and warrant B in the transaction. The company allowing the investor to purchase an aggregate of 1,411,764 shares of the company’s common stock with warrant A being a commitment fee of 705,882 shares of common stock, and warrant B being fully earned upon issuance as an additional commitment fee of 705,882 shares of common stock, provide that warrant B is returnable to the company upon the repayment of the note. The warrants will be exercisable into common shares at a price of $1.28 per share on pr after three-year anniversary. The notes bear an fixed coupon rate of 12% per annum and will be due on September 22, 2021. A lump-sum interest payment for one year shall be immediately due on announced date and shall be added to the principal balance and payable on the maturity date or upon acceleration or by prepayment or otherwise, notwithstanding the number of days which the principal is outstanding. Principal payments shall be made in six installments each in the amount of $100,000 commencing 180 days following the announcement date and continuing thereafter each 30 days for 5 months. Any amount of principal or interest on this note which is not paid when due shall bear interest at the rate of the lesser of 24% per annum and the maximum amount permitted under law from the due date thereof until the same is paid. The investor have a right to convert the notes into common stock in case of default. The company will close the deal in two tranche. The company will receive $100,000 on September 23, 2020 and remaining $500,000 on October 19, 2020. The company will issue securities pursuant to exemption provided under Regulation D
お知らせ • Sep 24Brain Scientific Inc. Announces Resignation Vadim Sakharov as Member of the Board of Directors, President and Chief Technology OfficerOn September 22, 2020, Vadim Sakharov, a member of the Board of Directors of Brain Scientific Inc. and its President and Chief Technology Officer, resigned from the Board and from all of his positions with the Company, effective immediately. The Company intends to continue to consult with Mr. Sakharov on terms to be determined.
お知らせ • Sep 04Brain Scientific Inc. announced that it has received $0.1425 million in funding from Diamond Investment Group II LLCBrain Scientific Inc. (OTCPK:BRSF) announced that it has entered into a securities purchase agreement with Diamond Investment Group II LLC for a private placement of an 8% convertible redeemable note for gross proceeds of $150,000 on September 1, 2020. The par value of the note is $157,500, which is issued at a discount of $7,500 in the transaction. The note is convertible into common shares of the company. The conversion price shall be equal to 60% of the lowest closing bid price for the common stock for the fifteen prior trading day period. The company shall have the right to pre-pay the entire remaining principal amount of the note from the issuance date until 180 days after the issuance date, upon 3 days’ notice to the investor, subject to the pre-payment terms. The note will mature on September 1, 2021. The note issued in the transaction is restricted in nature.
お知らせ • Aug 18+ 1 more updateBrain Scientific Inc. announced delayed 10-Q filingOn 08/17/2020, Brain Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.